Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.
Journal
Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
13
12
2018
revised:
23
05
2019
accepted:
03
06
2019
pubmed:
5
8
2019
medline:
5
8
2020
entrez:
5
8
2019
Statut:
ppublish
Résumé
Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.
Identifiants
pubmed: 31377122
pii: S2212-5345(18)30312-5
doi: 10.1016/j.resinv.2019.06.001
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
512-533Informations de copyright
Copyright © 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.